Mylan II B.V.
Mylan II B.V. (MYL): 68 pipeline candidates · ~10 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
9.9 months
N/A
Lead: Approved
68 candidates
N/A
N/A
A transparent, data-derived signal for Mylan II B.V.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$667.1M
Quarterly Burn
$807.1M
Runway
9.9 mo
Revenue
$3.0B
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (68 candidates)
| Drug | Phase |
|---|---|
| abiraterone | Approved |
| acamprosate | Approved |
| acetaminophen | Approved |
| acetazolamide | Approved |
| acitretin | Approved |
| alendronate | Approved |
| almotriptan malate | Approved |
| ambrisentan | Approved |
| apixaban | Approved |
| aprepitant | Approved |
Showing 10 of 68 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in Mylan II B.V.'s pipeline?
Mylan II B.V. (MYL) has 68 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Mylan II B.V.'s lead drug candidate?
Mylan II B.V.'s most advanced tracked candidate is abiraterone (Approved) for 1 INDICATIONS AND USAGE Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with • Metastatic castration-resistant prostate cancer (CRPC) • Metastatic high-risk castration-sensitive prostate cancer (CSPC) Abiraterone acetate tablets are a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with • metastatic castration-resistant prostate cancer (CRPC). ( 1 ) • metastatic high-risk castration-sensitive prostate cancer (CSPC). ( 1 ).
What is Mylan II B.V.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Mylan II B.V. has approximately 9.9 months of cash runway.
Who is the CEO of Mylan II B.V.?
Heather Bresch is the chief executive officer of Mylan II B.V. (MYL).
Get the full picture on Mylan II B.V.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.